Racura Oncology Ltd (ASX:RAC)
Australia · Delayed Price · Currency is AUD 2.590
-0.130 (-4.78%)
Apr 28, 2026, 4:10 PM AEST
Racura Oncology Earnings Call Transcripts
Fiscal Year 2025
-
Discovery of EE bisantrene as the sole active isomer led to three new patents, securing up to 25 years of exclusivity and significant commercial potential. RC110 is phase three ready, and partnering efforts focus on Asia-Pacific, with robust protocols ensuring only EE is administered.
Fiscal Year 2024
-
The AGM highlighted major progress in advancing RC220 to clinical trials, board renewal, and a focus on cardioprotection and anti-aging research. Shareholders approved key resolutions, and management emphasized strategic discipline, resource management, and commercialization opportunities.